Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical …
A Van Driessche, ZN Berneman… - The oncologist, 2012 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Explain
the role of the Wilm's tumor protein 1 (WT1) as a tumor antigen in peptide-and dendritic cell …
the role of the Wilm's tumor protein 1 (WT1) as a tumor antigen in peptide-and dendritic cell …
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
Y Oji, N Hashimoto, A Tsuboi… - … journal of cancer, 2016 - Wiley Online Library
We previously evaluated Wilms' tumor gene 1 (WT1) peptide vaccination in a large number
of patients with leukemia or solid tumors and have reported that HLA‐A* 24: 02 restricted, 9 …
of patients with leukemia or solid tumors and have reported that HLA‐A* 24: 02 restricted, 9 …
Prevalence of possible immune resistance mechanisms of acute leukemias within the context of vaccination strategies using the Wilms tumor gene-1 (WT1)
D Stather - 2012 - edoc.hu-berlin.de
The foregoing study investigated the immunogenicity of Wilms' tumor gene product 1 (WT1)-
peptide vaccination in WT1-expressing acute myeloid leukemia (AML) patients without …
peptide vaccination in WT1-expressing acute myeloid leukemia (AML) patients without …